PLoS ONE (Jan 2010)

Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer.

  • Victoria Gonzalo,
  • Juan José Lozano,
  • Jenifer Muñoz,
  • Francesc Balaguer,
  • Maria Pellisé,
  • Cristina Rodríguez de Miguel,
  • Montserrat Andreu,
  • Rodrigo Jover,
  • Xavier Llor,
  • M Dolores Giráldez,
  • Teresa Ocaña,
  • Anna Serradesanferm,
  • Virginia Alonso-Espinaco,
  • Mireya Jimeno,
  • Miriam Cuatrecasas,
  • Oriol Sendino,
  • Sergi Castellví-Bel,
  • Antoni Castells,
  • Gastrointestinal Oncology Group of the Spanish Gastroenterological Association

DOI
https://doi.org/10.1371/journal.pone.0008777
Journal volume & issue
Vol. 5, no. 1
p. e8777

Abstract

Read online

BackgroundColorectal cancer (CRC) multiplicity has been mainly related to polyposis and non-polyposis hereditary syndromes. In sporadic CRC, aberrant gene promoter methylation has been shown to play a key role in carcinogenesis, although little is known about its involvement in multiplicity. To assess the effect of methylation in tumor multiplicity in sporadic CRC, hypermethylation of key tumor suppressor genes was evaluated in patients with both multiple and solitary tumors, as a proof-of-concept of an underlying epigenetic defect.Methodology/principal findingsWe examined a total of 47 synchronous/metachronous primary CRC from 41 patients, and 41 gender, age (5-year intervals) and tumor location-paired patients with solitary tumors. Exclusion criteria were polyposis syndromes, Lynch syndrome and inflammatory bowel disease. DNA methylation at the promoter region of the MGMT, CDKN2A, SFRP1, TMEFF2, HS3ST2 (3OST2), RASSF1A and GATA4 genes was evaluated by quantitative methylation specific PCR in both tumor and corresponding normal appearing colorectal mucosa samples. Overall, patients with multiple lesions exhibited a higher degree of methylation in tumor samples than those with solitary tumors regarding all evaluated genes. After adjusting for age and gender, binomial logistic regression analysis identified methylation of MGMT2 (OR, 1.48; 95% CI, 1.10 to 1.97; p = 0.008) and RASSF1A (OR, 2.04; 95% CI, 1.01 to 4.13; p = 0.047) as variables independently associated with tumor multiplicity, being the risk related to methylation of any of these two genes 4.57 (95% CI, 1.53 to 13.61; p = 0.006). Moreover, in six patients in whom both tumors were available, we found a correlation in the methylation levels of MGMT2 (r = 0.64, p = 0.17), SFRP1 (r = 0.83, 0.06), HPP1 (r = 0.64, p = 0.17), 3OST2 (r = 0.83, p = 0.06) and GATA4 (r = 0.6, p = 0.24). Methylation in normal appearing colorectal mucosa from patients with multiple and solitary CRC showed no relevant difference in any evaluated gene.ConclusionsThese results provide a proof-of-concept that gene promoter methylation is associated with tumor multiplicity. This underlying epigenetic defect may have noteworthy implications in the prevention of patients with sporadic CRC.